Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/1572
Title: | Current issues in adjuvant treatment of stage II colon cancer | Authors: | André, Thierry Sargent, D Tabernero, J O'Connell, M BUYSE, Marc Sobrero, A Misset, J.L. Boni, C de Gramont, A |
Issue Date: | 2006 | Source: | ANNALS OF SURGICAL ONCOLOGY, 13(6). p. 887-898 | Abstract: | Adjuvant chemotherapy with 5-fluorouracil modulated by folinic acid, combined with oxaliplatin, has now become an accepted standard of care for patients with stage III colon cancer. In contrast, the use of adjuvant therapy for stage II patients remains controversial, and the identification of reliable prognostic factors to aid therapeutic decision making is crucial.| Methods: The authors critically review the results of clinical trials and meta-analyses investigating the value of adjuvant chemotherapy for stage II patients, emphasizing the heterogeneous nature of this population and the difficulty of performing clinical trials with sufficient power to reliably assess treatment efficacy. They also discuss the evidence concerning potential prognostic factors, particularly molecular markers.| Results: Available clinical trial data do not support the routine use of adjuvant chemotherapy for all stage II patients but suggest that it should be considered, particularly for certain high-risk patients. Recent guidelines advocate considering factors such as tumor differentiation, tumor perforation, number of lymph nodes examined, and T stage when assessing the likely benefit:risk ratio. Microsatellite instability and allelic imbalance seem to be strong predictors of good and poor prognosis, respectively, and in the near future, therapeutic decision-making models are likely to be further refined by the inclusion of such molecular markers.| Conclusions: There is growing evidence that the prognosis of certain stage II patients with unfavorable prognostic factors can be improved by adjuvant chemotherapy, and increasingly refined tools are now available to define those most likely to benefit. Referral of stage II patients for individual assessment is strongly recommended. | Keywords: | colon cancer, stage II; adjuvant chemotherapy; 5-fluorouracil; leucovorin; oxaliplatin; METASTATIC COLORECTAL-CANCER; AMERICAN JOINT COMMITTEE; MICROSATELLITE-INSTABILITY; DUKES-B; LYMPH-NODES; THYMIDYLATE SYNTHASE; PREDICT RECURRENCE; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; PLUS IRINOTECAN | Document URI: | http://hdl.handle.net/1942/1572 | ISSN: | 1068-9265 | e-ISSN: | 1534-4681 | DOI: | 10.1245/ASO.2006.07.003 | ISI #: | 000237571400021 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fulltext.pdf | Peer-reviewed author version | 147.63 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
77
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
77
checked on Aug 3, 2024
Page view(s)
56
checked on Sep 7, 2022
Download(s)
252
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.